Is ADC Therapeutics S.A. (ADCT) a Buy, Sell, or Hold?
ADC Therapeutics S.A.
NYSE:ADCT
$1.23 USD
-$0.02 (-1.6%)
- Volume
- 698.71K
- Average Volume
- 1.93M
- Market Capitalization
- $156.44M
- P/E Ratio
- -1.17
- Dividend Yield
- 0.00%
- Price Target
- $3.50
- Year High
- $4.98
- Year Low
- $0.78
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.09
Industry, Sector & symbol
| Stock Exchange | NYSE |
| CEO | Ameet Mallik |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ADCT |
| CUSIP | H0036K147 |
| CIK | 0001771910 |
| Web | https://www.adctherapeutics.com |
| Phone | 41 21 653 02 00 |
| Currency | USD |
| Employees | 188 |
| Country | CH |
Liquidity
| Debt-to-Equity Ratio | -0.54 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.09 |
| Quick Ratio | 4.02 |
| Cash Ratio | 3.42 |
Sales & Book Value
| Annual Sales | $81.36M |
| Price / Sales | 1.98 |
| Cash Flow | -0.74 |
| Price / Cash Flow | -1.37 |
| Price / Book | -0.88 |
Price Target and Rating
| Average Stock Price Forecast | $3.50 |
| High Stock Price Forecast | $5.00 |
| Low Stock Price Forecast | $2.00 |
| Forecast Upside/Downside | -64.86% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 12 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.12 |
| Trailing P/E Ratio | -1.17 |
| PEG Ratio | -0.04 |
| P/E Growth | -0.04 |
| Net Income | $-142.62M |
| Net Margin | -173.02% |
| Pretax Margin | -171.95% |
| Return on Equity | 65.27% |
| Return on Assets | -47.00% |
Financials Score
| AltmanZ Score | -7.64 |
| Piotroski Score | 3.00 |
| Working Capital | 209.14M |
| Total Assets | 291.5M |
| Ebit | -84.39M |
| Market Cap | 164.08M |
| Total Liabilities | 507.87M |
Poll Results
About ADC Therapeutics S.A. (NYSE:ADCT) Stock
ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients with relapsed or refractory DLBCL; and a Phase I trial for relapsed or refractory non-Hodgkin lymphoma (NHL). The company's pipeline also includes camidanlumab tesirine, another ADC, which has completed Phase I development for relapsed or refractory NHL. It is additionally progressing through Phase ... II for relapsed or refractory Hodgkin lymphoma and Phase Ib for selected advanced solid tumors. Furthermore, ADC Therapeutics is advancing ADCT-602, currently in Phase Ia for acute lymphoblastic leukemia, alongside ADCT-601 and ADCT-901, both of which are in Phase Ia for various solid tumors. Its preclinical portfolio features ADCT-701 and ADCT-901, both aimed at solid tumors. The company maintains strategic collaboration and license agreements with entities such as Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. Founded in 2011, ADC Therapeutics S.A. has its headquarters located in Epalinges, Switzerland.
ADC Therapeutics Announces New Employee Inducement Grant
2026-07-01 16:05:00
LAUSANNE, Switzerland, July 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 17,000 of the Company's common shares to a new employee on July 1, 2026 ("Grant"). The Grant was offered as material inducement to the employee's employment.
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
2026-06-30 07:15:00
100 r/r DLBCL patients treated at the selected 150 µg/kg dose of ZYNLONTA® plus glofitamab Full data expected in fourth quarter of 2026 LAUSANNE, Switzerland, June 30, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced the completion of enrollment in the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (r/r DLBCL). LOTIS-7 trial enrollment is now complete with 100 r/r DLBCL patients dosed at the selected 150 µg/kg dose of ZYNLONTA plus glofitamab.
2026-06-25 10:00:00
NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
2026-06-24 07:30:00
Planned ~17% workforce reduction expected to generate annualized estimated savings of approximately $10M, enhancing financial flexibility Company focused on delivering upcoming regulatory and clinical milestones, including planned LOTIS-5 sBLA submission and full LOTIS-7 data by end of 2026 LAUSANNE, Switzerland, June 24, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced a strategic reorganization to focus resources behind key value-driving initiatives in support of the ZYNLONTA® (loncastuximab tesirine-lpyl) franchise. As part of the reorganization, ADC Therapeutics plans to reduce its workforce globally by approximately 17 percent.
2026-06-23 17:50:00
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC” or the “Company”) (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
2026-06-18 10:00:00
NEW YORK, June 18, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
2026-06-16 17:36:00
NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC” or the “Company”) (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
2026-06-11 10:00:00
NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Frequently Asked Questions
-
What is the current ADC Therapeutics S.A. (ADCT) stock price?
-
ADC Therapeutics S.A.(NYSE:ADCT) stock price is $1.23 in the last trading session. During the trading session, ADCT stock reached the peak price of $4.98 while $0.78 was the lowest point it dropped to. The percentage change in ADCT stock occurred in the recent session was --1.6% while the dollar amount for the price change in ADCT stock was -$-0.02.
-
ADCT's industry and sector of operation?
-
The NYSE listed ADCT is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ADCT?
-
Jose I. Carmona | Chief Financial Officer
David S. Ege | Chief Technical Officer
Peter J. Graham | Secretary and Chief Legal & Compliance Officer
Kimberly Pope | Senior Vice President & Chief People Officer
Kristen Harrington-Smith | Chief Commercial Officer -
How many employees does ADCT have?
-
Number of ADCT employees currently stands at 188. ADCT operates from Biopole, Epalinges, VD 1066, CH.
-
Link for ADCT official website?
-
Official Website of ADCT is: https://www.adctherapeutics.com
-
How do I contact ADCT?
-
ADCT could be contacted at phone #41 21 653 02 00 and can also be accessed through its website. ADCT operates from Biopole, Epalinges, VD 1066, CH.
-
How many shares of ADCT are traded daily?
-
The average number of ADCT shares traded daily for last 3 months was 1.93M.
-
What is the market cap of ADCT currently?
-
The market value of ADCT currently stands at $156.44M with its latest stock price at $1.23